We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength?
Read MoreHide Full Article
Septerna, Inc. (SEPN - Free Report) shares soared 7% in the last trading session to close at $22.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 38% gain over the past four weeks.
The sudden surge in the stock price likely reflects the growing investor optimism regarding the potential of Septerna’s only clinical-pipeline candidate, SEP-631, which is being developed in an early-stage study for treating chronic spontaneous urticaria and other mast cell diseases. Earlier this year, the company signed a global collaboration and licensing deal worth up to $2.2 billion with Novo Nordisk to develop oral small-molecule therapies for obesity and cardiometabolic diseases. The partnership combines Septerna’s GPCR drug discovery expertise with NVO’s leadership and innovation in the field of obesity and cardiometabolic diseases.
This company is expected to post quarterly earnings of $0.19 per share in its upcoming report, which represents a year-over-year change of +102.3%. Revenues are expected to be $75 million, up 41566.7% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Septerna, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SEPN going forward to see if this recent jump can turn into more strength down the road.
Septerna, Inc. is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Gyre Therapeutics, Inc. (GYRE - Free Report) , finished the last trading session 0.4% higher at $7.3. GYRE has returned -5.2% over the past month.
For Gyre Therapeutics, Inc., the consensus EPS estimate for the upcoming report has changed -59.3% over the past month to $0.05. This represents a change of +150% from what the company reported a year ago. Gyre Therapeutics, Inc. currently has a Zacks Rank of #4 (Sell).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength?
Septerna, Inc. (SEPN - Free Report) shares soared 7% in the last trading session to close at $22.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 38% gain over the past four weeks.
The sudden surge in the stock price likely reflects the growing investor optimism regarding the potential of Septerna’s only clinical-pipeline candidate, SEP-631, which is being developed in an early-stage study for treating chronic spontaneous urticaria and other mast cell diseases. Earlier this year, the company signed a global collaboration and licensing deal worth up to $2.2 billion with Novo Nordisk to develop oral small-molecule therapies for obesity and cardiometabolic diseases. The partnership combines Septerna’s GPCR drug discovery expertise with NVO’s leadership and innovation in the field of obesity and cardiometabolic diseases.
This company is expected to post quarterly earnings of $0.19 per share in its upcoming report, which represents a year-over-year change of +102.3%. Revenues are expected to be $75 million, up 41566.7% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Septerna, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SEPN going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Septerna, Inc. is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Gyre Therapeutics, Inc. (GYRE - Free Report) , finished the last trading session 0.4% higher at $7.3. GYRE has returned -5.2% over the past month.
For Gyre Therapeutics, Inc., the consensus EPS estimate for the upcoming report has changed -59.3% over the past month to $0.05. This represents a change of +150% from what the company reported a year ago. Gyre Therapeutics, Inc. currently has a Zacks Rank of #4 (Sell).